Clover Health to Participate in Upcoming 2025 UBS Global Healthcare Conference
Clover Health (Nasdaq: CLOV) announced that its Chief Financial Officer, Peter Kuipers, will present at the 2025 UBS Global Healthcare Conference on Tuesday, November 11, 2025 at 11:00 a.m. Eastern Time.
A live webcast and replay will be available on Clover Health's investor relations website at https://investors.cloverhealth.com/.
Clover Health (Nasdaq: CLOV) ha annunciato che il suo Chief Financial Officer, Peter Kuipers, parteciperà alla 2025 UBS Global Healthcare Conference il martedì 11 novembre 2025 alle ore 11:00 Eastern Time.
Una trasmissione in diretta e la replica saranno disponibili sul sito delle relazioni con gli investitori di Clover Health all'indirizzo https://investors.cloverhealth.com/.
Clover Health (Nasdaq: CLOV) anunció que su Directora Financiera, Peter Kuipers, participará en la Conferencia Global de Atención Médica UBS 2025 el martes 11 de noviembre de 2025 a las 11:00 a.m. hora del Este.
Una transmisión en vivo y la repetición estarán disponibles en el sitio de relaciones con inversionistas de Clover Health en https://investors.cloverhealth.com/.
Clover Health (나스닥: CLOV)는 최고재무책임자 Peter Kuipers가 2025 UBS 글로벌 헬스케어 컨퍼런스에 2025년 11월 11일 화요일 오전 11:00 동부 표준시에 발표할 것이라고 발표했습니다.
생방송 웹캐스트 및 재생은 Clover Health의 투자자 관계 웹사이트 https://investors.cloverhealth.com/에서 이용하실 수 있습니다.
Clover Health (Nasdaq : CLOV) a annoncé que son directeur financier, Peter Kuipers, participera à la UBS Global Healthcare Conference 2025 le Mardi 11 novembre 2025 à 11h00, heure de l'Est.
Une diffusion en direct et une réplique seront disponibles sur le site des relations investisseurs de Clover Health à l'adresse https://investors.cloverhealth.com/.
Clover Health (Nasdaq: CLOV) kündigte an, dass sein Chief Financial Officer, Peter Kuipers, an der 2025 UBS Global Healthcare Conference am Dienstag, dem 11. November 2025, um 11:00 Uhr Eastern Time teilnehmen wird.
Eine Live-Webcast und die Wiederholung stehen auf der Investor-Relations-Website von Clover Health unter https://investors.cloverhealth.com/ zur Verfügung.
Clover Health (ناسداك: CLOV) أعلنت أن مديرها المالي، Peter Kuipers، سيشارك في مؤتمر الرعاية الصحية العالمي 2025 من UBS في الثلاثاء 11 نوفمبر 2025 الساعة 11:00 صباحاً بتوقيت شرق الولايات المتحدة.
سيكون هناك بث حي مباشر وإعادة عرض متاحان على موقع علاقات المستثمرين لش Clover Health على https://investors.cloverhealth.com/.
Clover Health(纳斯达克股票代码:CLOV) 宣布,其首席财务官 Peter Kuipers 将在 2025 UBS 全球医疗保健大会 上发言,时间为 2025年11月11日(星期二)美国东部时间11:00。
现场网络广播及重播将可在 Clover Health 的投资者关系网站 https://investors.cloverhealth.com/ 上获得。
- None.
- None.
WILMINGTON, Del., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Financial Officer, Peter Kuipers, will present at the 2025 UBS Global Healthcare Conference on Tuesday, November 11, 2025, at 11:00 a.m. Eastern Time.
A live webcast and replay of the presentation will be accessible on Clover Health's investor relations website at https://investors.cloverhealth.com/.
About Clover Health:
Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology’s impact on Medication Adherence, Congestive Heart Failure, and Chronic Obstructive Pulmonary Disease as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.
Investor Relations:
Ryan Schmidt
investors@cloverhealth.com
Press Inquiries:
press@cloverhealth.com
